Literature DB >> 18781855

Pharmacogenetic insights into codeine analgesia: implications to pediatric codeine use.

Parvaz Madadi1, Gideon Koren.   

Abstract

Codeine has been used medicinally since the 1800s as an analgesic and antitussive agent. Although very few studies have methodically examined the safety of codeine use in the pediatric age group, it is nonetheless commonly prescribed to children and breastfeeding mothers. Empirical evidence over the last century has suggested variability in the efficacy of codeine, and recent genomic advancements have shed important light on the mechanisms leading to such variability. Aside from evaluating the role of genetic variability in drug-metabolizing enzymes, receptors and transporters, the development of the blood-brain-barrier and the ontogeny of drug-metabolizing enzymes must also be considered in newborns and young children.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18781855     DOI: 10.2217/14622416.9.9.1267

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  25 in total

1.  Has the time come to phase out codeine?

Authors:  Noni MacDonald; Stuart M MacLeod
Journal:  CMAJ       Date:  2010-10-04       Impact factor: 8.262

Review 2.  Value of Supportive Care Pharmacogenomics in Oncology Practice.

Authors:  Jai N Patel; Lauren A Wiebe; Henry M Dunnenberger; Howard L McLeod
Journal:  Oncologist       Date:  2018-04-05

3.  National patterns of codeine prescriptions for children in the emergency department.

Authors:  Sunitha V Kaiser; Renee Asteria-Penaloza; Eric Vittinghoff; Glenn Rosenbluth; Michael D Cabana; Naomi S Bardach
Journal:  Pediatrics       Date:  2014-04-21       Impact factor: 7.124

4.  Oxycodone overdose in the pediatric population: case files of the University of Massachusetts Medical Toxicology Fellowship.

Authors:  Katherine L Boyle; Christopher D Rosenbaum
Journal:  J Med Toxicol       Date:  2014-09

5.  Impact of Safety-Related Regulations on Codeine Use in Children: A Quasi-Experimental Study Using Taiwan's National Health Insurance Research Database.

Authors:  Chih-Wan Lin; Ching-Huan Wang; Wei-I Huang; Wei-Ming Ke; Pi-Hui Chao; Wen-Wen Chen; Fei-Yuan Hsiao
Journal:  Drug Saf       Date:  2017-07       Impact factor: 5.606

6.  CYP2D6 pharmacogenetic and oxycodone pharmacokinetic association study in pediatric surgical patients.

Authors:  Rajiv Balyan; Marc Mecoli; Raja Venkatasubramanian; Vidya Chidambaran; Nichole Kamos; Smokey Clay; David L Moore; Jagroop Mavi; Chris D Glover; Peter Szmuk; Alexander Vinks; Senthilkumar Sadhasivam
Journal:  Pharmacogenomics       Date:  2017-02-17       Impact factor: 2.533

Review 7.  Drug interactions in childhood cancer.

Authors:  Cyrine Haidar; Sima Jeha
Journal:  Lancet Oncol       Date:  2010-09-22       Impact factor: 41.316

8.  Analgesic prescribing practices can be improved by low-cost point-of-care decision support.

Authors:  Glenn Rosenbluth; Stephen D Wilson; Judith H Maselli; Andrew D Auerbach
Journal:  J Pain Symptom Manage       Date:  2011-03-31       Impact factor: 3.612

9.  Apnea and oxygen desaturations in children treated with opioids after adenotonsillectomy for obstructive sleep apnea syndrome: a prospective pilot study.

Authors:  Justin D Khetani; Parvaz Madadi; Doron D Sommer; Desigen Reddy; Johanna Sistonen; Colin J D Ross; Bruce C Carleton; Michael R Hayden; Gideon Koren
Journal:  Paediatr Drugs       Date:  2012-12-01       Impact factor: 3.022

10.  CYP2D7-2D6 hybrid tandems: identification of novel CYP2D6 duplication arrangements and implications for phenotype prediction.

Authors:  Andrea Gaedigk; Uwe Fuhr; Charlene Johnson; L Anick Bérard; Dianne Bradford; J Steven Leeder
Journal:  Pharmacogenomics       Date:  2010-01       Impact factor: 2.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.